Tiziana Life Sciences to present clinical updates on intranasal foralumab at BIO-Europe 2023

Tiziana Life Sciences Ltd (NASDAQ:TLSA) will present at BIO-Europe in Munich, Germany, from November 6 to 8, 2023. The focus will be on clinical updates for intranasal foralumab, a human anti-CD3 monoclonal antibody, for treating neuroinflammatory and neurodegenerative diseases like secondary progressive multiple sclerosis and Alzheimer's. Matthew Davis, the company's COO and CMO, will present on November 8 at 10:00 CET. Tiziana's management will also engage in one-on-one partnering meetings during the event.